Abstract
Cognitive impairment is a shared abnormality between type 2 diabetes mellitus (T2DM) and many neurodegenerative and neuropsychiatric disorders, such as Alzheimer’s disease (AD) and schizophrenia. Emerging evidence suggests that brain insulin resistance plays a significant role in cognitive deficits, which provides the possibility of anti-diabetic agents repositioning to alleviate cognitive deficits. Both preclinical and clinical studies have evaluated the potential cognitive enhancement effects of anti-diabetic agents targeting the insulin pathway. Repurposing of anti-diabetic agents is considered to be promising for cognitive deficits prevention or control in these neurodegenerative and neuropsychiatric disorders. This article reviewed the possible relationship between brain insulin resistance and cognitive deficits. In addition, promising therapeutic interventions, especially current advances in anti-diabetic agents targeting the insulin pathway to alleviate cognitive impairment in AD and schizophrenia were also summarized.
Highlights
Cognitive deficits can be observed in neurodegenerative and neuropsychiatric disorders, such as Alzheimer’s disease (AD) and schizophrenia with demonstratable brain pathology(Taber et al, 2010)
Therapeutic interventions may be effective if both the periphery and brain glucose metabolic disruptions are alleviated for effective results
The molecular mechanism and preclinical animal models suggest that the repositioning of antidiabetic drugs is a promising opportunity to alleviate cognitive deficits in AD and schizophrenia
Summary
Cognitive deficits can be observed in neurodegenerative and neuropsychiatric disorders, such as AD and schizophrenia with demonstratable brain pathology(Taber et al, 2010).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
